Pemazyre, INN-Pemigatinib
Total Page:16
File Type:pdf, Size:1020Kb
25 February 2021 EMA/CHMP/105411/2021 Committee for Medicinal Products for Human Use (CHMP) Assessment report Pemazyre International non-proprietary name: pemigatinib Procedure No. EMEA/H/C/005266/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union Administrative information Name of the medicinal product: Pemazyre Applicant: Incyte Biosciences Distribution B.V. Paasheuvelweg 25 1105 BP Amsterdam NETHERLANDS Active substance: PEMIGATINIB International Non-proprietary Name/Common pemigatinib Name: Pharmaco-therapeutic group other antineoplastic agents, protein kinase (ATC Code): inhibitors (L01EX20) Therapeutic indication(s): Pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy. Pharmaceutical form(s): Tablet Strength(s): 4.5 mg, 9 mg and 13.5 mg Route(s) of administration: Oral use Packaging: blister (Aclar/PVC/paper/Alu) Package size(s): 14 tablets and 28 tablets Assessment report EMA/CHMP/105411/2021 Page 2/136 Table of contents 1. Background information on the procedure .............................................. 8 1.1. Submission of the dossier ..................................................................................... 8 1.2. Steps taken for the assessment of the product ...................................................... 10 2. Scientific discussion .............................................................................. 11 2.1. Problem statement ............................................................................................. 11 2.1.1. Disease or condition ........................................................................................ 11 2.1.2. Epidemiology and risk factors ........................................................................... 11 2.1.3. Biologic features, aetiology and pathogenesis ..................................................... 12 2.1.4. Clinical presentation, diagnosis and stage/prognosis ............................................ 12 2.1.5. Management ................................................................................................... 13 2.2. Quality aspects .................................................................................................. 15 2.2.1. Introduction.................................................................................................... 15 2.2.2. Active Substance ............................................................................................. 16 2.2.3. Finished Medicinal Product ................................................................................ 18 2.2.4. Discussion on chemical, pharmaceutical and biological aspects.............................. 22 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects ...................... 22 2.2.6. Recommendation(s) for future quality development ............................................. 22 2.3. Non-clinical aspects ............................................................................................ 23 2.3.1. Introduction.................................................................................................... 23 2.3.2. Pharmacology ................................................................................................. 23 2.3.3. Pharmacokinetics ............................................................................................ 28 2.3.4. Toxicology ...................................................................................................... 31 2.3.5. Ecotoxicity/environmental risk assessment ......................................................... 36 2.3.6. Discussion on non-clinical aspects ..................................................................... 36 2.3.7. Conclusion on the non-clinical aspects ............................................................... 40 2.4. Clinical aspects .................................................................................................. 40 2.4.1. Introduction.................................................................................................... 40 2.4.2. Pharmacokinetics ............................................................................................ 43 2.4.3. Pharmacodynamics .......................................................................................... 56 2.4.4. Discussion on clinical pharmacology ................................................................... 63 2.4.5. Conclusions on clinical pharmacology ................................................................. 66 2.5. Clinical efficacy .................................................................................................. 67 2.5.1. Dose response study(ies) ................................................................................. 67 2.5.2. Main study ..................................................................................................... 68 2.5.3. Discussion on clinical efficacy ............................................................................ 94 2.5.4. Conclusions on clinical efficacy .......................................................................... 99 2.6. Clinical safety .................................................................................................. 100 2.6.1. Discussion on clinical safety ............................................................................ 116 2.6.2. Conclusions on the clinical safety .................................................................... 122 Assessment report EMA/CHMP/105411/2021 Page 3/136 2.7. Risk Management Plan ...................................................................................... 122 2.8. Pharmacovigilance ........................................................................................... 123 2.9. New Active Substance ...................................................................................... 124 2.10. Product information ........................................................................................ 124 2.10.1. User consultation ......................................................................................... 124 2.10.2. Additional monitoring ................................................................................... 124 3. Benefit-Risk Balance ........................................................................... 125 3.1. Therapeutic Context ......................................................................................... 125 3.1.1. Disease or condition ...................................................................................... 125 3.1.2. Available therapies and unmet medical need ..................................................... 125 3.1.3. Main clinical studies ....................................................................................... 125 3.2. Favourable effects ............................................................................................ 125 3.3. Uncertainties and limitations about favourable effects ........................................... 126 3.4. Unfavourable effects ......................................................................................... 127 3.5. Uncertainties and limitations about unfavourable effects ....................................... 128 3.6. Effects Table .................................................................................................... 129 3.7. Benefit-risk assessment and discussion ............................................................... 130 3.7.1. Importance of favourable and unfavourable effects ............................................ 130 3.7.2. Balance of benefits and risks .......................................................................... 130 3.7.3. Additional considerations on the benefit-risk balance ......................................... 131 3.8. Conclusions ..................................................................................................... 132 4. Recommendations ............................................................................... 132 Assessment report EMA/CHMP/105411/2021 Page 4/136 List of abbreviations ALT Alanine aminotransferase AP Applicant's Part (or Open Part) of a DMF API Active Pharmaceutical Ingredient ASM Active Substance Manufacturer ASMF Active Substance Master File = Drug Master File AST Aspartate aminotransferase ATP adenosine triphosphate AUC area under the plasma concentration-time curve AUC0-24 area under the plasma concentration-time curve from Hour 0 to 24 AUC0-∞ area under the plasma concentration-time curve extrapolated to time of infinity BBB blood-brain barrier BCRP breast cancer resistant protein BCS Biopharmaceutics Classification System BDL Below the limit of detection b-FGF basic fibroblast growth factor BID twice daily BOR Best overall response BUN Urea nitrogen CEP Certificate of Suitability of the EP CFU Colony forming units CHMP Committee for Medicinal Products for Human use Cmax maximum observed plasma concentration CMS Concerned Member State CoA Certificate of Analysis CQA Critical